NASDAQ:OPHT - Ophthotech Stock Price, Price Target & More

$2.60 -0.03 (-1.14 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$2.63
Today's Range$2.58 - $2.67
52-Week Range$2.24 - $3.60
Volume120,174 shs
Average Volume285,032 shs
Market Capitalization$95.18 million
P/E Ratio0.83
Dividend YieldN/A
Beta1.36

About Ophthotech (NASDAQ:OPHT)

Ophthotech logoOphthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach and other gene delivery technologies to target retinal diseases. The company was founded in 2007 and is headquartered in New York, New York.

Receive OPHT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPHT
CUSIPN/A
Phone212-845-8200

Debt

Debt-to-Equity RatioN/A
Current Ratio13.69%
Quick Ratio13.69%

Price-To-Earnings

Trailing P/E Ratio0.83
Forward P/E Ratio-1.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$209.98 million
Price / Sales0.45
Cash Flow$3.2099 per share
Price / Cash0.81
Book Value$1.06 per share
Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)$3.17
Net Income$114.20 million
Net Margins26.69%
Return on Equity-230.07%
Return on Assets57.20%

Miscellaneous

Employees38
Outstanding Shares36,190,000

How to Become a New Pot Stock Millionaire

Ophthotech (NASDAQ:OPHT) Frequently Asked Questions

What is Ophthotech's stock symbol?

Ophthotech trades on the NASDAQ under the ticker symbol "OPHT."

How were Ophthotech's earnings last quarter?

Ophthotech (NASDAQ:OPHT) announced its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.58) by $0.32. Ophthotech had a net margin of 26.69% and a negative return on equity of 230.07%. During the same period last year, the company earned ($1.86) EPS. View Ophthotech's Earnings History.

When is Ophthotech's next earnings date?

Ophthotech is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Ophthotech.

What price target have analysts set for OPHT?

2 Wall Street analysts have issued 12 month price targets for Ophthotech's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Ophthotech's share price to reach $4.00 in the next year. View Analyst Ratings for Ophthotech.

Who are some of Ophthotech's key competitors?

Who are Ophthotech's key executives?

Ophthotech's management team includes the folowing people:
  • Dr. David R. Guyer, Chairman and Chief Exec. Officer (Age 58)
  • Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 62)
  • Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 57)
  • Mr. David F. Carroll M.B.A., CFO & Treasurer (Age 52)
  • Mr. Keith Westby M.B.A., Chief Operating Officer and Sr. VP (Age 43)

Has Ophthotech been receiving favorable news coverage?

Press coverage about OPHT stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.17 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.92 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Ophthotech?

Shares of OPHT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ophthotech's stock price today?

One share of OPHT stock can currently be purchased for approximately $2.60.

How big of a company is Ophthotech?

Ophthotech has a market capitalization of $95.18 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $114.20 million in net income (profit) each year or $3.17 on an earnings per share basis. Ophthotech employs 38 workers across the globe.

How can I contact Ophthotech?

Ophthotech's mailing address is ONE PENN PLAZA 19TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at 212-845-8200 or via email at [email protected]


MarketBeat Community Rating for Ophthotech (OPHT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe OPHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ophthotech (NASDAQ:OPHT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Ophthotech in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 53.85%. The high price target for OPHT is $4.00 and the low price target for OPHT is $4.00. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.501.502.002.00
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00$47.3333
Price Target Upside: 53.85% upside31.15% upside43.37% upside1,596.54% upside

Ophthotech (NASDAQ:OPHT) Consensus Price Target History

Price Target History for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ:OPHT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018JPMorgan ChaseDowngradeNeutral -> UnderweightLowView Rating Details
9/21/2017Stifel NicolausReiterated RatingHold$4.00LowView Rating Details
12/13/2016GabelliDowngradeBuy -> HoldN/AView Rating Details
12/13/2016Morgan StanleyDowngradeOverweight -> Equal WeightN/AView Rating Details
12/12/2016Goldman SachsUpgradeSell -> NeutralN/AView Rating Details
12/12/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
12/12/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
12/12/2016CowenDowngradeOutperform -> Market PerformN/AView Rating Details
12/12/2016CitigroupDowngradeBuy -> NeutralN/AView Rating Details
12/12/2016BarclaysDowngradeOverweight -> Equal WeightN/AView Rating Details
12/12/2016SunTrust BanksDowngradeBuy -> HoldN/AView Rating Details
12/12/2016Chardan CapitalDowngradeBuy -> Neutral$15.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Ophthotech (NASDAQ:OPHT) Earnings History and Estimates Chart

Earnings by Quarter for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ:OPHT) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.71 EPS
Next Year EPS Consensus Estimate: $-1.31 EPS

Ophthotech (NASDAQ OPHT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018        
2/27/2018Q4 2017($0.58)($0.26)$1.00 millionViewListenView Earnings Details
11/8/2017Q3 2017$4.38$5.25$185.00 million$206.65 millionViewN/AView Earnings Details
7/26/2017Q2 2017($1.07)($0.62)$1.38 million$1.66 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.31)($1.20)$1.94 million$1.66 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.64)($1.86)$6.27 million$5.32 millionViewN/AView Earnings Details
11/8/2016Q316($1.64)($1.71)$6.20 million$1.67 millionViewListenView Earnings Details
8/3/2016Q216($1.05)($0.85)$18.64 million$28.20 millionViewListenView Earnings Details
5/4/2016Q116($1.33)($1.03)$7.22 million$15.70 millionViewListenView Earnings Details
2/24/2016Q415($1.35)($1.02)$7.59 million$4.78 millionViewListenView Earnings Details
11/5/2015Q315($0.98)($1.14)$11.31 million$3.40 millionViewN/AView Earnings Details
8/5/2015Q215($1.02)($1.08)$2.77 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.75)$0.22$3.68 million$41.70 millionViewListenView Earnings Details
2/23/2015Q414($0.57)($1.06)$12.36 million$1.68 millionViewN/AView Earnings Details
11/11/2014Q314($0.62)$0.31$8.02 million$39.58 millionViewN/AView Earnings Details
8/6/2014Q214($0.56)($1.57)$4.31 millionViewN/AView Earnings Details
5/13/2014Q1($0.67)($0.64)ViewListenView Earnings Details
2/27/2014($0.50)($0.65)ViewN/AView Earnings Details
11/13/2013Q313($1.00)($10.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ophthotech (NASDAQ:OPHT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ophthotech (NASDAQ OPHT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 61.81%
Insider Trading History for Ophthotech (NASDAQ:OPHT)
Institutional Ownership by Quarter for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ OPHT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Glenn SblendorioInsiderSell6,838$2.69$18,394.2255,245View SEC Filing  
1/5/2018Barbara A WoodSVPSell602$3.17$1,908.3417,064View SEC Filing  
1/5/2018David R GuyerInsiderSell3,798$3.17$12,039.6642,458View SEC Filing  
1/5/2018Keith WestbyCOOSell317$3.17$1,004.8925,300View SEC Filing  
1/3/2018Keith WestbyCOOSell356$3.24$1,153.4424,956View SEC Filing  
1/2/2018Barbara A WoodSVPSell5,289$3.19$16,871.9120,472View SEC Filing  
1/2/2018David R GuyerInsiderSell16,520$3.19$52,698.8050,494View SEC Filing  
1/2/2018Glenn SblendorioCEOSell8,089$3.19$25,803.9144,584View SEC Filing  
7/5/2017Barbara A WoodSVPSell5,119$2.58$13,207.0213,451View SEC Filing  
7/5/2017David Francis CarrollCFOSell3,284$2.58$8,472.727,500View SEC Filing  
7/5/2017David R GuyerChairmanSell17,678$2.58$45,609.2437,692View SEC Filing  
7/5/2017Glenn SblendorioCEOSell7,828$2.58$20,196.2431,992View SEC Filing  
6/13/2017David E RedlickDirectorSell700$2.52$1,764.001,050View SEC Filing  
4/3/2017Glenn SblendorioCFOSell7,388$3.56$26,301.28View SEC Filing  
1/5/2017David R GuyerCEOSell3,785$4.96$18,773.6010,997View SEC Filing  
1/5/2017Henric Bjorn BjarkeSVPSell316$4.96$1,567.361,700View SEC Filing  
1/5/2017Samir Chandrakant PatelPresidentSell3,844$4.96$19,066.2418,332View SEC Filing  
1/3/2017Barbara A WoodSVPSell675$4.90$3,307.501,375View SEC Filing  
1/3/2017David R GuyerCEOSell3,484$4.90$17,071.608,231View SEC Filing  
1/3/2017Samir Chandrakant PatelPresidentSell2,999$4.90$14,695.1016,406View SEC Filing  
12/23/2016Barbara A. WoodSVPSell746$4.92$3,670.32View SEC Filing  
12/22/2016Glenn SblendorioCFOSell1,079$4.85$5,233.15View SEC Filing  
12/15/2016A/S NovoMajor ShareholderSell3,610,487$4.87$17,583,071.691,405,487View SEC Filing  
11/1/2016David R GuyerCEOSell22,060$35.61$785,556.6024,541View SEC Filing  
10/3/2016David R GuyerCEOSell22,060$44.37$978,802.2024,541View SEC Filing  
9/29/2016Samir Chandrakant PatelPresidentSell20,000$55.17$1,103,400.0024,239View SEC Filing  
8/29/2016Samir Chandrakant PatelPresidentSell20,000$52.80$1,056,000.00View SEC Filing  
8/1/2016David R GuyerCEOSell24,060$64.47$1,551,148.2056,451View SEC Filing  
7/29/2016Samir Chandrakant PatelPresidentSell20,000$64.21$1,284,200.00176,031View SEC Filing  
7/1/2016David R GuyerCEOSell24,060$52.12$1,254,007.2056,451View SEC Filing  
6/30/2016Samir Chandrakant PatelPresidentSell41,846$51.23$2,143,770.58174,992View SEC Filing  
6/3/2016Axel BolteDirectorBuy3,500$56.97$199,395.006,000View SEC Filing  
6/2/2016Glenn SblendorioCFOSell671$57.20$38,381.201,750View SEC Filing  
6/1/2016David R GuyerCEOSell30,060$52.71$1,584,462.6062,451View SEC Filing  
5/31/2016Samir Chandrakant PatelPresidentSell20,000$53.32$1,066,400.00213,377View SEC Filing  
5/24/2016A/S NovoMajor ShareholderSell1,300,000$49.00$63,700,000.003,610,489View SEC Filing  
5/2/2016David R GuyerCEOSell22,060$46.18$1,018,730.8054,451View SEC Filing  
4/29/2016Samir Chandrakant PatelPresidentSell20,000$46.79$935,800.00231,008View SEC Filing  
4/1/2016David R GuyerCEOSell22,060$44.11$973,066.6054,451View SEC Filing  
3/29/2016Samir Chandrakant PatelPresidentSell20,000$41.85$837,000.00248,410View SEC Filing  
3/1/2016David R GuyerCEOSell22,060$45.48$1,003,288.8054,451View SEC Filing  
2/29/2016Samir Chandrakant PatelPresidentSell20,000$45.13$902,600.00263,736View SEC Filing  
1/29/2016Samir Chandrakant PatelPresidentSell20,000$53.59$1,071,800.00260,911View SEC Filing  
1/28/2016David R. GuyerCEOSell18,598$53.63$997,410.7432,391View SEC Filing  
1/11/2016Nicholas GalakatosDirectorSell3,000$65.72$197,160.005,684View SEC Filing  
1/4/2016Barbara A. WoodSVPSell1,000$76.37$76,370.00746View SEC Filing  
12/30/2015David R. GuyerCEOSell18,582$78.82$1,464,633.2429,910View SEC Filing  
12/30/2015Glenn SblendorioDirectorSell2,000$80.00$160,000.00View SEC Filing  
12/29/2015Samir Chandrakant PatelPresidentSell1,184$77.50$91,760.00278,605View SEC Filing  
12/24/2015Samir Chandrakant PatelPresidentSell26,036$77.09$2,007,115.24278,605View SEC Filing  
12/10/2015Nicholas GalakatosDirectorSell3,000$64.44$193,320.007,684View SEC Filing  
12/1/2015Barbara A. WoodSVPSell2,000$63.24$126,480.00View SEC Filing  
11/30/2015David R. GuyerCEOSell18,582$62.49$1,161,189.1829,910View SEC Filing  
11/24/2015Samir Chandrakant PatelPresidentSell27,215$60.27$1,640,248.05278,605View SEC Filing  
11/18/2015Nicholas GalakatosDirectorSell1,500$60.00$90,000.009,684View SEC Filing  
11/5/2015Samir Chandrakant PatelPresidentSell20,687$53.55$1,107,788.85278,605View SEC Filing  
10/21/2015Samir Chandrakant PatelPresidentSell27,215$43.27$1,177,593.05259,292View SEC Filing  
10/16/2015Barbara A. WoodSVPSell2,000$45.00$90,000.00View SEC Filing  
9/29/2015David R. GuyerCEOSell18,582$37.69$700,355.5829,910View SEC Filing  
9/21/2015Samir Chandrakant PatelPresidentSell27,215$46.34$1,261,143.10259,292View SEC Filing  
8/31/2015David R. GuyerCEOSell18,582$44.88$833,960.1629,910View SEC Filing  
8/20/2015Samir Chandrakant PatelPresidentSell27,215$48.75$1,326,731.25259,292View SEC Filing  
7/20/2015Samir Chandrakant PatelPresidentSell27,215$67.87$1,847,082.05View SEC Filing  
7/17/2015Glenn SblendorioDirectorSell3,000$67.33$201,990.00View SEC Filing  
7/1/2015Barbara A WoodSVPSell2,000$51.94$103,880.00View SEC Filing  
6/29/2015David R GuyerCEOSell18,582$51.05$948,611.10View SEC Filing  
6/18/2015Samir Chandrakant PatelPresidentSell12,000$49.78$597,360.00View SEC Filing  
5/28/2015David R GuyerCEOSell18,582$48.62$903,456.84View SEC Filing  
4/29/2015David R GuyerCEOSell18,582$48.45$900,297.90View SEC Filing  
4/17/2015Samir Chandrakant PatelPresidentSell12,000$50.47$605,640.00View SEC Filing  
3/30/2015Axel BolteDirectorBuy500$48.27$24,135.00View SEC Filing  
3/30/2015David R GuyerCEOSell18,582$48.26$896,767.32View SEC Filing  
3/2/2015Barbara A WoodSVPSell2,000$53.26$106,520.00View SEC Filing  
3/2/2015David R GuyerCEOSell18,582$53.22$988,934.04View SEC Filing  
1/2/2015David R GuyerCEOSell15,034$45.34$681,641.56View SEC Filing  
11/13/2014A/S NovoMajor ShareholderSell995,000$40.20$39,999,000.00View SEC Filing  
11/3/2014David R GuyerCEOSell15,034$39.71$597,000.14View SEC Filing  
10/2/2014David R GuyerCEOSell2,807$38.52$108,125.64View SEC Filing  
10/2/2014Samir Chandrakant PatelPresidentSell1,965$38.04$74,748.60View SEC Filing  
10/1/2014David R GuyerCEOSell12,227$37.30$456,067.10View SEC Filing  
10/1/2014Samir Chandrakant PatelPresidentSell17,676$37.28$658,961.28View SEC Filing  
9/4/2014David R GuyerCEOSell1,107$38.58$42,708.06View SEC Filing  
8/1/2014Bruce PeacockCFOSell6,191$37.78$233,895.98View SEC Filing  
8/1/2014David R GuyerCEOSell13,136$37.85$497,197.60View SEC Filing  
8/1/2014Samir Chandrakant PatelPresidentSell18,986$37.80$717,670.80View SEC Filing  
7/1/2014Bruce PeacockCFOSell7,739$41.07$317,840.73View SEC Filing  
7/1/2014David R GuyerCEOSell15,034$41.08$617,596.72View SEC Filing  
7/1/2014Samir Chandrakant PatelPresidentSell18,986$41.08$779,944.88View SEC Filing  
6/16/2014Nicholas GalakatosDirectorSell144,976$44.17$6,403,589.92View SEC Filing  
6/11/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell211,680$45.42$9,614,505.60View SEC Filing  
6/4/2014Svlsf Iv, LlcMajor ShareholderSell1,966,935$42.54$83,673,414.90View SEC Filing  
6/3/2014Bruce PeacockCFOSell13,931$40.12$558,911.72View SEC Filing  
6/3/2014Svlsf Iv, LlcMajor ShareholderSell1,865,619$40.65$75,837,412.35View SEC Filing  
6/2/2014David R GuyerCEOSell25,417$39.92$1,014,646.64View SEC Filing  
6/2/2014Samir Chandrakant PatelPresidentSell27,873$39.91$1,112,411.43View SEC Filing  
5/30/2014Svlsf Iv, LlcMajor ShareholderSell931,869$40.99$38,197,310.31View SEC Filing  
5/28/2014Svlsf Iv, LlcMajor ShareholderSell980,127$40.19$39,391,304.13View SEC Filing  
5/23/2014Svlsf Iv, LlcMajor ShareholderSell330,450$38.10$12,590,145.00View SEC Filing  
5/13/2014Hbm Healthcare Investments (Camajor shareholderSell500,000$29.75$14,875,000.003,139,902View SEC Filing  
5/1/2014Bruce PeacockCFOSell4,643$32.43$150,572.49View SEC Filing  
5/1/2014David GuyerCEOSell10,665$33.71$359,517.1511,891View SEC Filing  
5/1/2014Samir Chandrakant PatelPresidentSell14,319$32.45$464,651.55104,472View SEC Filing  
3/24/2014Bruce PeacockCFOSell6,137$34.77$213,383.49View SEC Filing  
3/24/2014David GuyerCEOSell12,027$34.53$415,292.3134,583View SEC Filing  
3/24/2014Samir Chandrakant PatelPresidentSell16,876$34.54$582,897.04135,667View SEC Filing  
2/18/2014Svlsf Iv, Llcmajor shareholderSell2,111,364$29.61$62,517,488.04140,228View SEC Filing  
9/30/2013A/S NovoInsiderBuy455,000$22.00$10,010,000.00View SEC Filing  
9/30/2013Hbm Healthcare Investments (CaMajor ShareholderBuy228,000$22.00$5,016,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ophthotech (NASDAQ OPHT) News Headlines

Source:
DateHeadline
Ophthotech (OPHT) Upgraded to "Buy" at ValuEngineOphthotech (OPHT) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 8 at 11:17 AM
Ophthotech (OPHT) Given Consensus Recommendation of "Hold" by BrokeragesOphthotech (OPHT) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 5 at 5:40 PM
Insider Selling: Ophthotech (OPHT) Insider Sells 6,838 Shares of StockInsider Selling: Ophthotech (OPHT) Insider Sells 6,838 Shares of Stock
www.americanbankingnews.com - April 3 at 11:04 PM
Ophthotech (OPHT) Rating Lowered to D+ at TheStreetOphthotech (OPHT) Rating Lowered to D+ at TheStreet
www.americanbankingnews.com - March 24 at 12:11 PM
Regeneron Eylea Hits 24-Week Primary Endpoint in Study - Nasdaq ... - NasdaqRegeneron Eylea Hits 24-Week Primary Endpoint in Study - Nasdaq ... - Nasdaq
www.nasdaq.com - March 21 at 8:40 AM
Regeneron Eylea Hits 24-Week Primary Endpoint in StudyRegeneron Eylea Hits 24-Week Primary Endpoint in Study
finance.yahoo.com - March 21 at 8:39 AM
Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In ... - BenzingaEeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In ... - Benzinga
www.benzinga.com - March 20 at 8:19 AM
Ophthotech (OPHT) Rating Lowered to Underweight at JPMorgan Chase & Co.Ophthotech (OPHT) Rating Lowered to Underweight at JPMorgan Chase & Co.
www.americanbankingnews.com - March 19 at 10:59 AM
Ophthotech Corp (OPHT) Receives Consensus Recommendation of "Hold" from BrokeragesOphthotech Corp (OPHT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 11 at 6:18 PM
Ophthotech (OPHT) Stock Rating Lowered by Zacks Investment ResearchOphthotech (OPHT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 7 at 12:49 PM
Stonepine Capital Management LLC Lowers Holdings in Ophthotech Corp (OPHT)Stonepine Capital Management LLC Lowers Holdings in Ophthotech Corp (OPHT)
www.americanbankingnews.com - March 6 at 2:56 PM
Tamarack Advisers LP Has $2.34 Million Position in Ophthotech Corp (OPHT)Tamarack Advisers LP Has $2.34 Million Position in Ophthotech Corp (OPHT)
www.americanbankingnews.com - March 6 at 10:30 AM
Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference - Business Wire (press release)Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference - Business Wire (press release)
www.businesswire.com - March 6 at 8:09 AM
Ophthotech to Present at the Cowen and Company 38th Annual Health Care ConferenceOphthotech to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:09 AM
Ophthotech Corp (OPHT) Position Reduced by Bogle Investment Management L P DEOphthotech Corp (OPHT) Position Reduced by Bogle Investment Management L P DE
www.americanbankingnews.com - March 6 at 5:04 AM
Ophthotech (OPHT) Downgraded by ValuEngine to HoldOphthotech (OPHT) Downgraded by ValuEngine to Hold
www.americanbankingnews.com - March 4 at 12:48 PM
Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results - Business Wire (press release)Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results - Business Wire (press release)
www.businesswire.com - March 1 at 8:09 AM
Ophthotechs (OPHT) CEO Glenn Sblendorio on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaOphthotech's (OPHT) CEO Glenn Sblendorio on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 1 at 8:09 AM
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus - NasdaqOphthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus - Nasdaq
www.nasdaq.com - March 1 at 8:09 AM
Blog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal DiseasesBlog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal Diseases
finance.yahoo.com - March 1 at 8:09 AM
Ophthotech (OPHT) Given New $4.00 Price Target at Chardan CapitalOphthotech (OPHT) Given New $4.00 Price Target at Chardan Capital
www.americanbankingnews.com - February 28 at 4:34 PM
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in FocusOphthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
www.zacks.com - February 28 at 8:11 AM
Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating ResultsOphthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
finance.yahoo.com - February 27 at 5:59 PM
Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease StrategyOphthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy
finance.yahoo.com - February 27 at 5:59 PM
Ophthotech (OPHT) Announces  Earnings Results, Beats Estimates By $0.29 EPSOphthotech (OPHT) Announces Earnings Results, Beats Estimates By $0.29 EPS
www.americanbankingnews.com - February 27 at 9:12 AM
Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy - Business Wire (press release)Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy - Business Wire (press release)
www.businesswire.com - February 27 at 8:12 AM
Ophthotech (OPHT) Scheduled to Post Earnings on TuesdayOphthotech (OPHT) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 22 at 1:16 PM
Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - Business Wire (press release)Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - Business Wire (press release)
www.businesswire.com - February 21 at 8:15 AM
Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018
finance.yahoo.com - February 21 at 8:15 AM
Ophthotech Corp (OPHT) Given Average Rating of "Buy" by AnalystsOphthotech Corp (OPHT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 14 at 5:34 PM
Ophthotech Corp (OPHT) Receives Average Recommendation of "Buy" from BrokeragesOphthotech Corp (OPHT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 5:38 PM
Ophthotech Begins Phase II Zimura Study in Stargardt DiseaseOphthotech Begins Phase II Zimura Study in Stargardt Disease
www.zacks.com - January 17 at 10:10 AM
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of ...Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of ...
www.businesswire.com - January 16 at 4:38 PM
Ophthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for Treatment of STGD1Ophthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for Treatment of STGD1
www.streetinsider.com - January 16 at 4:38 PM
Ophthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for ... - StreetInsider.comOphthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for ... - StreetInsider.com
www.streetinsider.com - January 16 at 10:14 AM
Ophthotech Corp (OPHT) Elects Jane Pritchett Henderson to Board - StreetInsider.comOphthotech Corp (OPHT) Elects Jane Pritchett Henderson to Board - StreetInsider.com
www.streetinsider.com - January 16 at 10:14 AM
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of DirectorsOphthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors
finance.yahoo.com - January 16 at 10:14 AM
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)
finance.yahoo.com - January 16 at 10:14 AM
Technical Perspectives on Biotech Stocks -- Ophthotech, Trevena, PTC Therapeutics, and Halozyme Therapeutics - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- Ophthotech, Trevena, PTC Therapeutics, and Halozyme Therapeutics - PR Newswire (press release)
www.prnewswire.com - January 10 at 10:21 AM
Ophthotech (OPHT) & Flex Pharma (FLKS) Head-To-Head AnalysisOphthotech (OPHT) & Flex Pharma (FLKS) Head-To-Head Analysis
www.americanbankingnews.com - January 9 at 3:42 PM
Ophthotech Corp (OPHT) Insider Sells $12,039.66 in StockOphthotech Corp (OPHT) Insider Sells $12,039.66 in Stock
www.americanbankingnews.com - January 5 at 6:50 PM
David R. Guyer Sells 16,520 Shares of Ophthotech Corp (OPHT) StockDavid R. Guyer Sells 16,520 Shares of Ophthotech Corp (OPHT) Stock
www.americanbankingnews.com - January 3 at 7:54 PM
Glenn Sblendorio Sells 8,089 Shares of Ophthotech Corp (OPHT) StockGlenn Sblendorio Sells 8,089 Shares of Ophthotech Corp (OPHT) Stock
www.americanbankingnews.com - January 3 at 7:54 PM
Insider Selling: Ophthotech Corp (OPHT) SVP Sells 5,289 Shares of StockInsider Selling: Ophthotech Corp (OPHT) SVP Sells 5,289 Shares of Stock
www.americanbankingnews.com - January 3 at 7:54 PM
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan ... - Business Wire (press release)Ophthotech Corporation to Present at the 36th Annual J.P. Morgan ... - Business Wire (press release)
www.businesswire.com - January 2 at 10:33 PM
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare ConferenceOphthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 10:07 AM
ValuEngine Downgrades Ophthotech (OPHT) to HoldValuEngine Downgrades Ophthotech (OPHT) to Hold
www.americanbankingnews.com - January 1 at 2:20 PM
Comparing Ophthotech (OPHT) and Its RivalsComparing Ophthotech (OPHT) and Its Rivals
www.americanbankingnews.com - December 28 at 3:21 AM
Ophthotech Corp (OPHT) Receives Average Recommendation of "Buy" from AnalystsOphthotech Corp (OPHT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 26 at 6:46 PM
Critical Review: Ophthotech (OPHT) versus The CompetitionCritical Review: Ophthotech (OPHT) versus The Competition
www.americanbankingnews.com - December 23 at 3:07 AM

SEC Filings

Ophthotech (NASDAQ:OPHT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ophthotech (NASDAQ:OPHT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ophthotech (NASDAQ OPHT) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.